![Cyrill Zimmermann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Cyrill Zimmermann was the founder of Adamant Biomedical Investments AG, founded in 2000, where the title held was Chief Executive Officer.
Dr. Zimmermann is currently Partner & Chief Executive Officer at ATG Healthcare Investments AG, starting in 2025.
Former positions include Portfolio Manager at Bellevue Asset Management AG from 2015 to 2025.
Postes actifs de Cyrill Zimmermann
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Cyrill Zimmermann
| Sociétés | Poste | Fin |
|---|---|---|
Bellevue Asset Management AG
 Bellevue Asset Management AG Investment ManagersFinance Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach that aims to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. | Head-Equity Investments | 01/08/2025 |
Adamant Biomedical Investments AG
 Adamant Biomedical Investments AG Investment ManagersFinance Adamant is a specialist investment manager investing in the biotechnology, medical technology and specialty pharmaceuticals sectors. Within these sectors, they invest in European and US equity. The firm's investment philosophy emphasizes fundamental research and leveraging an active network of scientists, doctors and financial experts to profit from the growth of the biomedical market. The firm manages their three portfolio sectors complementarily, the biotechnology sector providing opportunities for growth, medical technology offering sustainability, and specialty pharmaceuticals supplying stability. Demographics and medical breakthroughs are the major factors influencing Adamant's investment approach, as well as fundamental financial analysis at the company level. The management team includes experienced biomedical specialists with industry, research and asset management backgrounds. | Fondateur | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
32
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Bellevue Asset Management AG
Bellevue Asset Management AG Investment ManagersFinance Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach that aims to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. | Finance |
Adamant Biomedical Investments AG
Adamant Biomedical Investments AG Investment ManagersFinance Adamant is a specialist investment manager investing in the biotechnology, medical technology and specialty pharmaceuticals sectors. Within these sectors, they invest in European and US equity. The firm's investment philosophy emphasizes fundamental research and leveraging an active network of scientists, doctors and financial experts to profit from the growth of the biomedical market. The firm manages their three portfolio sectors complementarily, the biotechnology sector providing opportunities for growth, medical technology offering sustainability, and specialty pharmaceuticals supplying stability. Demographics and medical breakthroughs are the major factors influencing Adamant's investment approach, as well as fundamental financial analysis at the company level. The management team includes experienced biomedical specialists with industry, research and asset management backgrounds. | Finance |
